GenVec Inc. (GNVC) Reports Preclinical Research At American Association for Cancer Research Showing TNFerade Effective Against Metastases In Melanoma Model And Demonstrating Targeting In Ovarian Cancer Model
10/19/2005 5:13:13 PM
GAITHERSBURG, Md.--(BUSINESS WIRE)--April 20, 2005--GenVec, Inc. (Nasdaq:GNVC) announced the presentation of two posters at the American Association for Cancer Research (AACR), currently ongoing in Anaheim, California. The first poster, "Local Therapy with TNFerade(TM) and Radiation Suppresses Metastatic Disease in the Spontaneously Metastatic B16F10 Melanoma Model," showed that TNFerade significantly reduced the spread (metastasis) of the cancer to lymph nodes in a mouse model of melanoma.
In a second poster, researchers from GenVec and its partner, Fuso Pharmaceutical Industries Ltd. of Japan, presented preclinical data demonstrating successful targeting and efficacious treatment in an ovarian cancer mouse model using a next generation targeted vector to deliver the tumor necrosis factor-alpha (TNF-alpha) gene. This poster is entitled "Tumor Targeting of Adenoviral Vectors Combined with Selective TNF Gene Expression is Effective and Well-Tolerated in Models of Ovarian Cancer." Both research posters are accessible through the company's website.